Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle

Basit Öğe Kaydı
dc.authoridsogutlu, fatma/0000-0002-1210-7660
dc.authoridAvci, Cigir Biray/0000-0001-8251-4520
dc.authorscopusid58303505900
dc.authorscopusid57203588534
dc.authorscopusid26022436600
dc.authorscopusid57212299393
dc.authorwosidsogutlu, fatma/ABE-2054-2020
dc.contributor.authorTurkmen, Ecem
dc.contributor.authorSogutlu, Fatma
dc.contributor.authorErdogan, Mehmet
dc.contributor.authorBiray Avci, Cigir
dc.date.accessioned2024-08-25T18:45:45Z
dc.date.available2024-08-25T18:45:45Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractAnaplastic thyroid cancer (ATC) represents the type with the worst prognosis among thyroid cancers. In ATC with a highly invasive phenotype, selective targeting of TERT with BIBR1532 may be a goal-driven approach to preserving healthy tissues. In present study, it was aimed to investigate the effects of treatment of SW1736 cells with BIBR1532 on apoptosis, cell cycle progression, and migration. The apoptotic effect of BIBR1532 on SW1736 cells was examined using the Annexin V method, the cytostatic effect using cell cycle test, migration properties using wound healing assay. Gene expression differences were determined by real-time qRT-PCR and differences in protein level by ELISA test. BIBR1532-treated SW1736 cells had 3.1-fold increase in apoptosis compared to their untreated counterpart. There was 58.1% arrest in the G(0)/G(1) phase and 27.6% arrest in the S phase of the cell cycle in untreated group, treatment with BIBR1532 increased cell population in G(0)/G(1) phase to 80.9% and decreased in S phase to 7.1%. Treatment with the TERT inhibitor resulted in a 50.8% decrease in cell migration compared to the untreated group. After BIBR1532 treatment of SW1736 cells, upregulation of BAD, BAX, CASP8, CYCS, TNFSF10, CDKN2A genes, and downregulation of BCL2L11, XIAP, CCND2 genes were detected. BIBR1532 treatment resulted in an increase in BAX and p16 proteins, and a decrease in concentration of BCL-2 protein compared to untreated group. Targeting TERT with BIBR1532 as a mono drug or using of BIBR1532 at priming stage prior to chemotherapy treatment in ATC may present a novel and promising treatment strategy.en_US
dc.description.sponsorshipEge University Faculty of Medicine Scientific Research Projects Coordinatorship [TGA-2021-22392]en_US
dc.description.sponsorshipThis study was supported by Ege University Faculty of Medicine Scientific Research Projects Coordinatorship with project number TGA-2021-22392.en_US
dc.identifier.doi10.1007/s12032-023-02063-0
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue7en_US
dc.identifier.pmid37284891en_US
dc.identifier.scopus2-s2.0-85161064081en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-023-02063-0
dc.identifier.urihttps://hdl.handle.net/11454/101688
dc.identifier.volume40en_US
dc.identifier.wosWOS:001003018900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectAnaplastic thyroid canceren_US
dc.subjectBIBR1532en_US
dc.subjectApoptosisen_US
dc.subjectTERTen_US
dc.subjectMigrationen_US
dc.subjectPhase-Ii Trialen_US
dc.subjectCarcinomaen_US
dc.subjectHterten_US
dc.subjectSorafeniben_US
dc.titleEvaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycleen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu